Mankind Pharma has announced its acquisition of Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of Rs 13,630 crore. This strategic move positions Mankind Pharma as a leader in India's women's health and fertility drug market, increasing its market share to 13% in the Rs 11,000 crore gynaecology market. The acquisition includes BSV's robust R&D capabilities and established complex tech platforms, enhancing Mankind's product portfolio in critical care and women's health. BSV, which reported revenues of Rs 1,723 crore in FY24, has shown a 20% year-on-year growth. The deal, expected to close within 3-4 months, will be funded through internal accruals and a mix of debt and equity.